基于人体等效剂量的蟾酥量—效关系探讨

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (6): 655-658.

基于人体等效剂量的蟾酥量—效关系探讨

马宏跃^1,2, 段金廒¹, 周婧¹, 唐于平¹, 潘苏华², 丁安伟¹

¹江苏省方剂研究重点实验室,²南京中医药大学药学院临床药学教研室, 南京 210046, 江苏

收稿日期:2009-02-12 修回日期:2009-06-24 出版日期:2009-06-26 发布日期:2020-10-27
通讯作者: 段金廒, 男, 教授, 博导, 研究方向:中药方剂研究。Tel:025-85811116 E-mail:dja@njut cm.edu.cn
作者简介:马宏跃,男,博士,讲师,研究方向:中药临床药学。Tel:025-85811625 E-mail:hongyuema@126.com

Approach on Ch'an su dosage-effect relationship based on the human equivalent dose

MA Hong-yue^1,2, DUAN Jing-ao¹, ZHOU Jing¹, TANG Yu-ping¹, PAN Su-hua², DING An-wei¹

¹Key Laboratory for Modern Research of Chinese Medical Formulae of Jiangsu, ²Department of Clinical Pharmacy of College of Pharmacy Nanjing University of Chinese Medicine, Nanjing 210046, Jiangsu, China

Received:2009-02-12 Revised:2009-06-24 Online:2009-06-26 Published:2020-10-27

摘要/Abstract

摘要： 目的: 探讨中药材蟾酥的量—效毒关系。方法: 引用相关整体动物有效剂量的文献数据, 根据体表面积法换算药材蟾酥的人体等效剂量(HED) 。结果: 折算蟾酥抗炎的HED 为9.8～39.2 mg/日, 抗肿瘤HED 为53.7～104.7 mg/日,毒性HED 为162～585.4 mg/日。结论: 蟾酥用于炎症治疗的HED 较小, 接近甚至低于药典推荐用量(15～30 mg/日), 提示其临床用量具有一定科学、合理性;但分析显示抗肿瘤的HED 较高, 其上限与蟾酥中毒的HED 接近, 提示中药材蟾酥用于肿瘤的中医处方剂量需谨慎设计。

关键词: 蟾酥, 人体等效剂量(HED), 量—效关系

Abstract: AIM: To approach the clinical dosageeffect relationship of Ch'an su. METHODS: The paper was performed by quoting/Literature data with animal effective doses to converse Ch'an su human equivalent dose (HED) range according to body surface area law. RESULTS: Ch'an su anti-inflammationHED was 9.8-39.2 mg/d, Ch'an su anti-tumor HED was 53.7-104.7 mg/d, the adverse reaction HED was 162-585.4 mg/d. CONCLUSION: Ch'an su anti-inflammation HED was smaller than the recommended dosage (15-30 mg/d), which suggested the clinical dosage is scientific and reasonable.But the anti-tumor HED was high, the upper limit and the HED dosege of secnetio bufonis poisoning were close, which suggested the dosage of Ch'an su for the clinical treatment of tumor should be designed cautiously.

Key words: Ch'an su, human equivalent dose, dose-effect relationship

中图分类号:

R285

马宏跃, 段金廒, 周婧, 唐于平, 潘苏华, 丁安伟. 基于人体等效剂量的蟾酥量—效关系探讨[J]. 中国临床药理学与治疗学, 2009, 14(6): 655-658.

MA Hong-yue, DUAN Jing-ao, ZHOU Jing, TANG Yu-ping, PAN Su-hua, DING An-wei. Approach on Ch'an su dosage-effect relationship based on the human equivalent dose[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(6): 655-658.

参考文献

[1] 张庆, 许军.对健康成人志愿者进行临床试验的药物安全起始剂量估计[J].中国新药杂志, 2005, 14(7):893-895.
[2] 黄继汉, 黄晓晖, 陈志扬, 等.药理试验中动物间和动物与人体间的等效剂量换算[J].中国临床药理学与治疗学, 2004, 9(9):1069-1072.
[3] Masayasu K, Eizaburo O, Takeshi M, et al.Fundamental research for the pharmacological activity of oriental drugs. IX.On the combined action of several crude drugs consisting in “Rokusingan” for the anti-inflammatory effect[J]. Yakugaku Zasshi, 1968, 88(22):135-139.
[4] 马宏跃.六神丸抗感染性炎症物质基础与作用机制研究[D].中国药科大学2007 届博士学位论文, 70-83.
[5] 杨琳, 段鹏飞, 王琼, 等.蟾酥脂溶性提取物的分离分析及其镇痛、抗肿瘤作用研究[J].氨基酸和生物资源, 2006, 29(1):64-67.
[6] 赵明芳, 刘云鹏, 金波, 等.蟾蜍毒素对H22 荷瘤小鼠疗效及毒副作用的实验研究[J].肿瘤防治杂志,2005, 12(22):1705-1709.
[7] 李墨林, 舒晓宏, 刘用楫, 等.蟾酥对小鼠膀胱癌的抗癌作用研究[J].中医药学刊, 2004, 22(4):651-652.
[8] 高瑞霖, 邵义祥.蟾酥提取物对荷瘤小鼠肿瘤细胞形态学实验研究[J].交通医学, 2006, 20(4):376-378.
[9] 朱大诚, 尹小明, 陈秀珍, 等.蟾酥对可移植性小鼠淋巴细胞白血病疗效的研究[J].时珍国医国药,2007, 18(11):2645-2647.
[10] 齐卫红, 李欣, 沈连忠, 等.Beagle 犬经口给予六神丸急性毒性研究[J].毒理学杂志, 2007, 21(4):303-304.
[11] 宋亿楠, 鲁福德, 宋小军, 等.蟾酥对实验犬心电图影响的研究[J].心脏杂志, 2005, 17(4):404.
[12] 魏仲南, 陈莫京.急性蟾酥中毒1 例[J].福建中医药, 1993, 24(2):15.
[13] 周从容, 刘橄.蟾酥中毒致快速型心律失常2 例[J].中国社区医师, 2004, 6(22):66.
[14] 周月芳, 刘瑞林.急性蟾酥中毒致心的损害一例报告[J].青海医药杂志, 1988, 106(6):57-58.
[15] 蒋涛.内服蟾酥急性中毒致死1 例报告[J].新疆中医药, 2002, 20(4):17-18.